61 related articles for article (PubMed ID: 28696020)
1. Rise of oligodendroglioma hypermutator phenotype from a subclone harboring TP53 mutation after TMZ treatment.
Higuchi F; Uzuka T; Matsuda H; Sumi T; Iwata K; Namatame T; Shin M; Akutsu H; Ueki K
Brain Tumor Pathol; 2024 Apr; 41(2):80-84. PubMed ID: 38294664
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: long term results of RTOG BR0131.
Vogelbaum MA; Hu C; Peereboom DM; Macdonald DR; Giannini C; Suh JH; Jenkins RB; Laack NN; Brachman DG; Shrieve DC; Souhami L; Mehta MP
J Neurooncol; 2015 Sep; 124(3):413-20. PubMed ID: 26088460
[TBL] [Abstract][Full Text] [Related]
3. Procarbazine, lomustine and vincristine or temozolomide: which is the better regimen?
Lassman AB
CNS Oncol; 2015; 4(5):341-6. PubMed ID: 26544062
[TBL] [Abstract][Full Text] [Related]
4. TCF12 is mutated in anaplastic oligodendroglioma.
Labreche K; Simeonova I; Kamoun A; Gleize V; Chubb D; Letouzé E; Riazalhosseini Y; Dobbins SE; Elarouci N; Ducray F; de Reyniès A; Zelenika D; Wardell CP; Frampton M; Saulnier O; Pastinen T; Hallout S; Figarella-Branger D; Dehais C; Idbaih A; Mokhtari K; Delattre JY; Huillard E; Mark Lathrop G; Sanson M; Houlston RS;
Nat Commun; 2015 Jun; 6():7207. PubMed ID: 26068201
[TBL] [Abstract][Full Text] [Related]
5. Mutant IDH inhibitors induce lineage differentiation in IDH-mutant oligodendroglioma.
Spitzer A; Gritsch S; Nomura M; Jucht A; Fortin J; Raviram R; Weisman HR; Gonzalez Castro LN; Druck N; Chanoch-Myers R; Lee JJY; Mylvaganam R; Lee Servis R; Fung JM; Lee CK; Nagashima H; Miller JJ; Arrillaga-Romany I; Louis DN; Wakimoto H; Pisano W; Wen PY; Mak TW; Sanson M; Touat M; Landau DA; Ligon KL; Cahill DP; Suvà ML; Tirosh I
Cancer Cell; 2024 May; 42(5):904-914.e9. PubMed ID: 38579724
[TBL] [Abstract][Full Text] [Related]
6. CyberKnife Radiosurgery for Extracranial Metastases of Oligodendroglioma: A Clinical Case Report.
Shaghaghian E; Park DJ; Yoo KH; Meola A; Chang SD
Cureus; 2023 Dec; 15(12):e51035. PubMed ID: 38264380
[TBL] [Abstract][Full Text] [Related]
7. Definition of primary and secondary glioblastoma--response.
Ohgaki H; Burger P; Kleihues P
Clin Cancer Res; 2014 Apr; 20(7):2013. PubMed ID: 24557936
[No Abstract] [Full Text] [Related]
8. Correction to: [
Krebs S; Grommes C; McDevitt MR; Carlin SD; O'Donoghue JA; Graham MS; Young RJ; Schöder H; Gutin PH; Bander NH; Osborne JR
Eur J Nucl Med Mol Imaging; 2022 May; 49(6):2102. PubMed ID: 35266033
[No Abstract] [Full Text] [Related]
9. Mutational spectrum of ATRX aberrations in neuroblastoma and associated patient and tumor characteristics.
van Gerven MR; Bozsaky E; Matser YAH; Vosseberg J; Taschner-Mandl S; Koster J; Tytgat GAM; Molenaar JJ; van den Boogaard M
Cancer Sci; 2022 Jun; 113(6):2167-2178. PubMed ID: 35384159
[TBL] [Abstract][Full Text] [Related]
10. Practice of the New Integrated Molecular Diagnostics in Gliomas: Experiences and New Findings in a Single Chinese Center.
Hu WM; Wang F; Xi SY; Zhang X; Lai JP; Wu HY; Liu LL; Sai K; Zeng J
J Cancer; 2020; 11(6):1371-1382. PubMed ID: 32047544
[No Abstract] [Full Text] [Related]
11. Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicenter study.
Ahluwalia MS; Xie H; Dahiya S; Hashemi-Sadraei N; Schiff D; Fisher PG; Chamberlain MC; Pannullo S; Newton HB; Brewer C; Wood L; Prayson R; Elson P; Peereboom DM
J Neurooncol; 2015 Mar; 122(1):111-9. PubMed ID: 25534576
[TBL] [Abstract][Full Text] [Related]
12. Treatment recommendations for anaplastic oligodendrogliomas that are codeleted.
Anderson MD; Gilbert MR
Oncology (Williston Park); 2013 Apr; 27(4):315-20, 322. PubMed ID: 23781695
[TBL] [Abstract][Full Text] [Related]
13. Low-grade and anaplastic oligodendroglioma.
Van Den Bent MJ; Bromberg JE; Buckner J
Handb Clin Neurol; 2016; 134():361-80. PubMed ID: 26948366
[TBL] [Abstract][Full Text] [Related]
14. Complete durable response of a pediatric anaplastic oligodendroglioma to temozolomide alone: Case report and review of literature.
Sorge C; Li R; Singh S; Reddy AT; Solomon DA; Perry A; Friedman GK
Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28696020
[TBL] [Abstract][Full Text] [Related]
15. Comparative molecular analysis of primary and recurrent oligodendroglioma that acquired imbalanced 1p/19q codeletion and TP53 mutation: a case report.
Ono T; Reinhardt A; Takahashi M; Nanjo H; Kamataki A; von Deimling A; Shimizu H
Acta Neurochir (Wien); 2020 Dec; 162(12):3019-3024. PubMed ID: 32785787
[TBL] [Abstract][Full Text] [Related]
16. Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma.
Thomas AA; Abrey LE; Terziev R; Raizer J; Martinez NL; Forsyth P; Paleologos N; Matasar M; Sauter CS; Moskowitz C; Nimer SD; DeAngelis LM; Kaley T; Grimm S; Louis DN; Cairncross JG; Panageas KS; Briggs S; Faivre G; Mohile NA; Mehta J; Jonsson P; Chakravarty D; Gao J; Schultz N; Brennan CW; Huse JT; Omuro A
Neuro Oncol; 2017 Oct; 19(10):1380-1390. PubMed ID: 28472509
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
